THE EFFICACY OF RADIOIODINE THERAPY IN PATIENTS WITH GRAVES' DISEASE

Anna M. Dąbrowska¹, Jolanta Kijek², Jerzy S. Tarach¹, Anna Toruń-Jurkowska³, Beata Chrapko², Maria Kurowska¹



¹ Chair and Department of Endocrinology, Medical University of Lublin, Poland ² Chair and Department of Nuclear Medicine, Medical University of Lublin, Poland ³ Department of Mathematics and Medical Biostatistics, Medical University of Lublin, Poland


INTRODUCTION: Radioiodine (RAI) has been used for the treatment of Graves' hyperthyroidism since 1940s. It is relatively safe and considered as one of the definitive therapies. Achievement of euthyroidism or hypothyroidism is defined as a successful therapy.

METHODS: The study was conducted in 366 patients (80.60% of women) with Graves' disease (GD), aged 46.76 ± 13.52 years. We analyzed retrospectively hormonal and imaging findings (scintigraphy, ultrasonography), including isotopic results in subjects treated at Department of Nuclear Medicine and at Endocrinology Department during the eight-year period. The efficacy of RAI therapy has been assessed based on free thyroid hormones levels, measured 12 months after radioiodine administration.


RESULTS


- Mean concentrations of thyroid hormones before therapy were: FT4 38.40 ± 22.17 (12.0-22.0pmol/l) and FT3 21.9 ± 17.11 (3.0-7.0pmol/l)
- The thyroid mass was estimated to be 69.67 ± 38.87g.
- Mean RAI 24-h uptake was 63.93 ± 16.15% and therapeutic activity of RAI, calculated using Marinelli's formula, was 544.28 ± 176.35MBq.
- The used thyroid-absorbed doses of RAI (Gy) were: ≤ 120, > 120 and ≤ 150, > 150 (49.18% vs 46.99% vs 3.83% of subjects with GD, respectively).

FIG.1 The results of RAI therapy




HYPERTHYROIDISM SIGNIFICANTLY AN EFFECTIVE OF CURE WAS CORRELATED WITH LOWER: thyroid mass / RAI 24-h uptake / administered dose






- · No significant associations between successful therapy and:
- patients' age / levels of free thyroid hormones before therapy / thyroid absorbed dose were found.

FIG. 2 The efficacy of RAI therapy



Effective RAI therapy - 63.66% (64.75% of F, 59.15% of M with GD)

Ineffective RAI therapy - 36.34% (35.25% of F, 40.85% of M with GD)



<u>CONCLUSIONS:</u> RAI therapy was <u>effective</u> in 63.66% of patients with GD. Females responded <u>better</u> to treatment than males. The cure correlated with thyroid mass, RAI 24-h uptake and dose of radioiodine.

18th European Congress of Endocrinology, 28-31.05.2016 MUNICH, GERMANY





